tbuckley/cabot-search huggingface dataset:
Abstract P120: Increased [ca <sup>2+</sup> ] <sub>e</sub> Enhances Adipocyte Development In Bone Marrow Stroma
Authors: Ryota Hashimoto, Youichi Katoh, Seigo Itoh, Takafumi Iesaki, Hiroyuki Daida, Yuji Nakazato, Takao Okada
Journal: Circulation Research (2011)

Background: Bone marrow stroma contains adipocytes, osteoblasts, and lymphohematopoietic donor cells. With age, fatty marrow gradually predominates in bone marrow stroma and is a factor underlying age-related fracture and anemia. Thus, it is important to understand the mechanism of adipocyte development in bone marrow stroma. Bone marrow Ca 2+ levels can reach high concentrations of 8 to 40 mM, while circulating plasma Ca 2+ levels normally range from 2.3 to 2.6 mM. However, the effects of a high extracellular calcium concentration ([Ca 2+ ] e ) on adipocyte development in bone marrow stroma remain largely unknown. Methods and Results: We studied the effects of high [Ca 2+ ] e on adipocyte development in bone marrow stroma. First, we used the fura-2 method to examine whether a change in [Ca 2+ ] e alters [Ca 2+ ] i levels in bone marrow stromal cells. Changes of [Ca 2+ ] e from 1.8 mM to 5.4 mM and 10.8 mM significantly increased [Ca 2+ ] i by 1.1 and 1.3 times, respectively. Next, bone marrow stromal cells were cultured for 14 days in high [Ca 2+ ] e (5.4 mM and 10.8 mM) and normal [Ca 2+ ] e (1.8 mM) conditions. Adipocyte development was monitored by Oil Red O staining of cytoplasmic lipids and by the activity of glycerol-3-phosphate dehydrogenase (GPDH). In 5.4 mM and 10.8 mM [Ca 2+ ] e , Oil Red O-stained cells increased significantly by 1.4 and 2.3 times, respectively, and GPDH activity increased significantly by 1.7 and 2.3 times, respectively, compared with the respective values in 1.8 mM [Ca 2+ ] e . Conclusions: These results indicate that high [Ca 2+ ] e induces an increase of [Ca 2+ ] i , which enhances adipocyte development in bone marrow stroma. Further studies are required to determine the influx pathway of Ca 2+ , since prevention of Ca 2+ influx into bone marrow stromal cells might suppress development of fatty marrow and reduce age-related fracture and anemia.
A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
Authors: Robert J. Motzer, Viktor Grünwald, Thomas E. Hutson, Camillo Porta, Thomas Powles, Masatoshi Eto, Corina E. Dutcus, Mahadi Ali Baig, Lea Dutta, Di Li, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2018)

TPS706 Background: Lenvatinib (LEN) is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, and RET and KIT. Based on a phase 2 study (Motzer et al. Lancet Oncol. 2015), LEN was approved in combination with everolimus (EVE) for the treatment of metastatic renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy. A phase 1b/2 study of LEN in combination with pembrolizumab (PEM) in patients (pts) with RCC LEN is also underway. We report the design of a multicenter, open-label, phase 3 trial of LEN plus EVE or PEM vs sunitinib (SUN; a standard therapy for RCC) as first-line treatment for advanced RCC. Methods: Pts aged ≥ 18 years with confirmed advanced RCC diagnosis, ≥ 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Karnofsky Performance Status ≥ 70, controlled blood pressure, and adequate blood coagulation, renal, hepatic, and bone marrow function are eligible. Pts will be randomized 1:1:1 to receive LEN 18 mg/d + EVE 5 mg/d, LEN 20 mg/d + PEM 200 mg every 3 wks, or SUN 50 mg/d (on a schedule of 4 wks on treatment followed by 2 wks off) until disease progression, unacceptable toxicity, withdrawal of consent, or study end. The primary endpoint is to show superiority of LEN+EVE or LEN+PEM over single-agent SUN as first-line treatment for advanced RCC in improving progression-free survival (PFS). Secondary endpoints include comparison of objective response rate, overall survival, PFS on next-line therapy, health-related quality of life, and safety and tolerability in pts receiving LEN+EVE or LEN+PEM vs SUN. Exploratory endpoints include PFS in the LEN+PEM arm using immune-related RECIST, comparison of duration of response, disease control rate, and clinical benefit rate in pts treated with LEN+EVE or LEN+PEM vs SUN, and analysis of the relationship between blood biomarkers and outcome. No interim analysis is planned for efficacy or futility. Enrollment of 735 pts is planned to achieve 90% power at 2-sided α = 0.05 to detect a difference in ≥ 1 of the primary comparisons. Clinical trial information: NCT02811861.
Alta sensibilidad de la vigilancia de la tuberculosis en el sistema de vigilancia nacional integrado en Finlandia
Authors: M Kokki, P Holmström, P Ruutu
Journal: Eurosurveillance (2005)

Hay pocos datos sobre la sensibilidad de la vigilancia de la tuberculosis en Finlandia desde la integracion en 1987 del sistema de vigilancia y de control especifico de esa enfermedad en el sistema general de salud. Se compararon las declaraciones en rutina de Mycobacterium tuberculosis realizadas por los laboratorios al Registro nacional de las enfermedades infecciosas (National Infectious Disease Register, NIDR) entre el 1 de Enero 1995 y el 31 Diciembre 1996, con los datos recogidos independientemente de todos los laboratorios que realizan cultivo de M. tuberculosis y con los datos de los registros medicos de los pacientes. Se identificaron 1.059 casos con cultivo positivo. La sensibilidad global del NIDR fue del 93% (984/1.059). El valor predictivo positivo de un caso positivo por cultivo en el NIDR de ser un verdadero caso confirmado por cultivo fue del 99%. En cuanto a los casos confirmados por cultivo en el NIDR, el 89% fueron notificados por uno o varios medicos. Se puede disponer de un sistema muy sensible de notificacion de los casos de tuberculosis confirmados por cultivo por medio de un sistema de vigilancia integrado de las enfermedades infecciosas basado en las declaraciones de laboratorios.
Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5‐trisphosphate receptor
Authors: Tanaporn Khamphaya, Natsasi Chukijrungroat, Vitoon Saengsirisuwan, Kisha A. Mitchell‐Richards, Marie E. Robert, Albert Mennone, Meenakshisundaram Ananthanarayanan, Michael H. Nathanson, Jittima Weerachayaphorn
Journal: Hepatology (2017)

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide. It may result in several types of liver problems, including impaired liver regeneration (LR), but the mechanism for this is unknown. Because LR depends on calcium signaling, we examined the effects of NAFLD on expression of the type II inositol 1,4,5-trisphosphate receptor (ITPR2), the principle calcium release channel in hepatocytes. ITPR2 promoter activity was measured in Huh7 and HepG2 cells. ITPR2 and c-Jun protein levels were evaluated in Huh7 cells, in liver tissue from a rat model of NAFLD, and in liver biopsy specimens of patients with simple steatosis and nonalcoholic steatohepatitis (NASH). LR was assessed in wild-type and Itpr2 knockout (Itpr2-/- ) mice following 67% hepatectomy. Cell proliferation was examined in ITPR2-knockout HepG2 cells generated by the CRISPR/Cas9 system. c-Jun dose dependently decreased activity of the human ITPR2 promoter. c-Jun expression was increased and ITPR2 was decreased in fat-loaded Huh7 cells and in livers of rats fed a high-fat, high-fructose diet. Overexpression of c-Jun reduced protein and mRNA expression of ITPR2 in Huh7 cells, whereas knockdown of c-Jun prevented the decrease of ITPR2 in fat-loaded Huh7 cells. ITPR2 expression was decreased and c-Jun was increased in liver biopsies of patients with steatosis and NASH compared to controls. ITPR2-knockout cells exhibited less nuclear calcium signaling and cell proliferation than control cells. LR assessed by Ki-67 and proliferating cell nuclear antigen was markedly decreased in Itpr2-/- mice. Conclusion: Fatty liver induces a c-Jun-mediated decrease in ITPR2 in hepatocytes. This may account for the impaired LR that occurs in NAFLD. (Hepatology 2018;67:560-574).
Low Incidence of End-Stage Renal Disease in Childhood-Onset Type 1 Diabetes Followed for Up to 42 Years
Authors: Vibeke Gagnum, Maryam Saeed, Lars C. Stene, Torbjørn Leivestad, Geir Joner, Torild Skrivarhaug
Journal: Diabetes Care (2017)

OBJECTIVE End-stage renal disease (ESRD) is one of the most severe complications in type 1 diabetes. We aimed to estimate the cumulative incidence of ESRD in individuals with childhood-onset type 1 diabetes followed for up to 42 years. RESEARCH DESIGN AND METHODS Data were based on the nationwide, population-based Norwegian Childhood Diabetes Registry and included case patients with new-onset type 1 diabetes (age &amp;lt;15 years) who had received a diagnosis during the periods 1973–1982 and 1989–2012. Follow-up took place until the development of ESRD, death, emigration, or 30 November 2015. We estimated the cumulative incidence of ESRD by linking to the Norwegian Renal Registry. RESULTS Among the 7,871 patients, representing 147,714 person-years of follow-up, ESRD developed in 103 individuals (1.3%). The mean time from the diagnosis of diabetes to the development of ESRD was 25.9 years (range 12.7–39.1). The cumulative incidence of ESRD was 0.7% (95% CI 0.4–1.0) at 20 years’ diabetes duration, 2.9% (2.3–3.7) at 30 years’ duration, and 5.3% (4.3–6.5) at 40 years’ duration. The risk of the development of ESRD was lower in women than in men (hazard ratio [HR] 0.61; 95% CI 0.41–0.91) and higher in individuals in whom diabetes had been diagnosed at 10–14 years of age compared with those in whom it was diagnosed before 10 years of age (HR 1.29; 1.06–1.56). We did not identify any significant difference in the risk of the development of ESRD between those in whom diabetes was diagnosed in 1973–1982 and in 1989–2012 (HR 0.80; 0.45–1.45). CONCLUSIONS We report a very low incidence of ESRD among patients with childhood-onset diabetes in Norway. The risk was lower in women compared with men and in individuals in whom diabetes was diagnosed at a younger age.
Réponse à un cas suspect de diphtérie à Dordrecht, Pays-Bas
Authors: J. E. van Steenbergen, A Leentvaar-Kuijpers, J H C T van den Kerkhof
Journal: Eurosurveillance (1996)

De 25 000 a 50 000 refugies cherchent asile aux Pays-Bas chaque annee. Apres verification juridique immediate, 85% a 90% d'entre eux sont transferes dans l'un des 14 centres dits d'accueil ou ils sont testes pour la tuberculose, et les enfants et les personnes âgees sont examines par un medecin. Le statut vaccinal des enfants de moins de 18 ans est evalue puis complete selon le standard hollandais (diphterie-coqueluche-tetanos, vaccin inactive contre la polio, rougeole-oreillons-rubeole (ROR) et, pour les refugies, vaccin BCG). Environ quatre mois plus tard, les refugies sont transferes dans un des 14 centres ou hotels pour refugies, ou ils sejournent pendant un ou deux ans jusqu'a l'obtention d'un statut officiel de refugie. Par la suite, on les aide a trouver un logement approprie.
The first report of multicenter validation study of 95-gene classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients
Authors: T. Kinoshita, K. Aogi, M. Takahashi, K-I. Ito, T. Oba, N. Shiroma, K. Arihiro, F. Tsukamoto, S. Shiino, M. Yoshida, S. Ohsumi
Journal: Annals of Oncology (2017)
Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study
Authors: S. Gadgeel, S. Peters, T.S.K. Mok, A.T. Shaw, D-W. Kim, S-H.I. Ou, M. Perol, R. Dziadziuszko, J.S. Ahn, R. Rosell, A. Zeaiter, E. Mitry, E. Nueesch, B. Balas, R. Camidge
Journal: Annals of Oncology (2017)
Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program
Authors: B. Rapoport, D. Vorobiof, L. Dreosti, A. Nosworthy, G. Mcadam, A. Jordaan, M. De Necker, J. De Beer, H. Duvenhage
Journal: Annals of Oncology (2017)
Biomarker prevalence study and phase I trial of afatinib in children with malignant tumours
Authors: K. Nysom, P. Leblond, D. Frappaz, I. Aerts, P. Varlet, F. Giangaspero, M. Gambart, D. Hargrave, L. Marshall, P. Kearns, G. Makin, S. Gallego, M. Kieran, M. Casanova, A. Lahogue, S. Wind, B. Stolze, D. Roy, M. Uttenreuther-Fischer, B. Geoerger
Journal: Annals of Oncology (2017)
Abstract 13586: Early Initiation of Oral Intake in Adult Patients After Cardiothoracic Surgery is Safe and Reduces Thirst: Results of a Randomized Clinical Trial
Authors: Catherine Ford, Donna McCormick, Wei Teng, Janet Parkosewich
Journal: Circulation (2015)

Aim: Tradition-based care dictates that patients fast for several hours post-cardiothoracic (CT) surgery due to concerns for adverse events (nausea, vomiting, dysphagia, aspiration pneumonia), although evidence is lacking to support this practice. Prolonged fasting causes patients significant distress from thirst. Our aim was to determine the effect of an early liberal regimen of ice chips and water on adverse events and thirst after CT surgery. We hypothesized that a liberal regimen vs. usual care (UC) would not increase adverse events and would reduce thirst. Method: We used a randomized controlled trial design with a sample of 149 patients from an 18-bed CTICU. Written informed consent was obtained and patients were randomized to UC (6-hour fast post-extubation) or liberal regimen during the pre-operative visit. After fasting 1 hour post-extubation, patients in the liberal regimen were first assessed with a 6-item protocol for oral intake readiness, and then offered ice chips. An hour later, they were advanced to water. Results: The mean age was 66±12.4 years; 73.8% were male; 91.3% had coronary artery and/or valve surgery. The two groups were equivalent except for the post-operative mean dose of ketorolac that was higher in the UC group (p=.04). The table below shows no differences in nausea, vomiting, or dysphagia between the UC vs. liberal group, and no aspiration pneumonia. Complaints of high thirst levels 6 hours after extubation were greater in the UC group. In analysis adjusted for relevant demographic and clinical variables (logistic regression), patients in the liberal group were less likely to report high thirst levels, compared with UC patients (B=-.299, OR=.273, 95% CI .118-.630). Conclusion: Early initiation of ice chips and water post-extubation after CT surgery was not associated with adverse events, but was associated with significantly less thirst. In appropriate patients, early oral intake can reduce thirst, a distressing symptom.
Verso l’ottimizzazione della sorveglianza della resistenza ai farmaci antitubercolari in Europa
Authors: M. C. Raviglione, M A Espinal
Journal: Eurosurveillance (2000)

In questi ultimi dieci anni, il potenziamento della sorveglianza della tubercolosi (TB) e diventata una priorita di sanita pubblica in Europa. Mentre nell’Europa occidentale, la precedente tendenza alla diminuzione dell’incidenza di casi di TB si e attenuata, in Europa orientale sono stati registrati drammatici aumenti dei tassi, spesso raddoppiati (1). Questa situazione ha portato gli epidemiologi e gli esperti di sanita pubblica a riconsiderare come monitorare il corso dell’epidemia. E’ diventato presto evidente che non esisteva nessuno standard chiaro di sorveglianza. Le definizioni e i sistemi informativi differivano molto tra paese e paese, il che rendeva molto difficile i confronti internazionali a livello regionale.
A virtual asthma clinic for children: fewer routine outpatient visits, same asthma control
Authors: Lara S. van den Wijngaart, Jolt Roukema, Annemie L.M. Boehmer, Marianne L. Brouwer, Cindy A.C. Hugen, Laetitia E.M. Niers, Arwen J. Sprij, Eleonora R.V.M. Rikkers-Mutsaerts, Bart L. Rottier, A. Rogier T. Donders, Chris M. Verhaak, Mariëlle W. Pijnenburg, Peter J.F.M. Merkus
Journal: European Respiratory Journal (2017)

eHealth is an appealing medium to improve healthcare and its value (in addition to standard care) has been assessed in previous studies. We aimed to assess whether an eHealth intervention could improve asthma control while reducing 50% of routine outpatient visits. In a multicentre, randomised controlled trial with a 16-month follow-up, asthmatic children (6–16 years) treated in eight Dutch hospitals were randomised to usual care (4-monthly outpatient visits) and online care using a virtual asthma clinic (VAC) (8-monthly outpatient visits with monthly web-based monitoring). Outcome measures were the number of symptom-free days in the last 4 weeks of the study, asthma control, forced expiratory volume in 1 s, exhaled nitric oxide fraction, asthma exacerbations, unscheduled outpatient visits, hospital admissions, daily dose of inhaled corticosteroids and courses of systemic corticosteroids. We included 210 children. After follow-up, symptom-free days differed statistically between the usual care and VAC groups (difference of 1.23 days, 95% CI 0.42–2.04; p=0.003) in favour of the VAC. In terms of asthma control, the Childhood Asthma Control Test improved more in the VAC group (difference of 1.17 points, 95% CI 0.09–2.25; p=0.03). No differences were found for other outcome measures. Routine outpatient visits can partly be replaced by monitoring asthmatic children via eHealth.
Anesthetics and Cognitive Impairments in Developing Children
Authors: Vesna Jevtovic-Todorovic
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
HCFC2 is needed for IRF1- and IRF2-dependent <i>Tlr3</i> transcription and for survival during viral infections
Authors: Lei Sun, Zhengfan Jiang, Victoria A. Acosta-Rodriguez, Michael Berger, Xin Du, Jin Huk Choi, Jianhui Wang, Kuan-wen Wang, Gokhul K. Kilaru, Jennifer A. Mohawk, Jiexia Quan, Lindsay Scott, Sara Hildebrand, Xiaohong Li, Miao Tang, Xiaoming Zhan, Anne R. Murray, Diantha La Vine, Eva Marie Y. Moresco, Joseph S. Takahashi, Bruce Beutler
Journal: The Journal of Experimental Medicine (2017)

Transcriptional regulation of numerous interferon-regulated genes, including Toll-like receptor 3 (Tlr3), which encodes an innate immune sensor of viral double-stranded RNA, depends on the interferon regulatory factor 1 (IRF1) and IRF2 transcription factors. We detected specific abrogation of macrophage responses to polyinosinic-polycytidylic acid (poly(I:C)) resulting from three independent N-ethyl-N-nitrosourea-induced mutations in host cell factor C2 (Hcfc2). Hcfc2 mutations compromised survival during influenza virus and herpes simplex virus 1 infections. HCFC2 promoted the binding of IRF1 and IRF2 to the Tlr3 promoter, without which inflammatory cytokine and type I IFN responses to the double-stranded RNA analogue poly(I:C) are reduced in mouse macrophages. HCFC2 was also necessary for the transcription of a large subset of other IRF2-dependent interferon-regulated genes. Deleterious mutations of Hcfc2 may therefore increase susceptibility to diverse infectious diseases.
Promoting sunscreen use and sun-protective practices in NCAA athletes: Impact of SUNSPORT educational intervention for student-athletes, athletic trainers, and coaches
Authors: Mina S. Ally, Susan M. Swetter, Kelsey E. Hirotsu, Justin Gordon, David Kim, Ashley Wysong, Lindsy Donnelly, Shufeng Li, Kristin M. Nord
Journal: Journal of the American Academy of Dermatology (2017)
CLASS-05 trial: A randomized controlled phase III trial of cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) + systemic chemotherapy vesus systemic chemotherapy alone for patients with limited peritoneal carcinomatosis of gastric cancer
Authors: H. Liu, G. Li, J. Yu, X. Su, Y. Sun, J. Hu, L. Huang, Z. Zhou, Y. Li, J. Yu, H. Wei, J. Peng, Z. Wu, H. Chen, S. Cui, Y. Hu
Journal: Annals of Oncology (2017)
A Transplantable Malignant Hemangioendothelioma of the Liver in the Mouse
Authors: Jesse E. Edwards, Howard B. Andervont, Albert J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1942)

Journal Article A Transplantable Malignant Hemangioendothelioma of the Liver in the Mouse Get access Jesse E. Edwards, Jesse E. Edwards research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard B. Andervont, Howard B. Andervont principal biologist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Albert J. Dalton Albert J. Dalton research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 5, April 1942, Pages 479–490, https://doi.org/10.1093/jnci/2.5.479 Published: 01 April 1942
A novel multimodal treatment strategy for cancer cachexia; rationale and motivation for the MENAC (Multimodal – Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Authors: S. Kaasa, B. Laird, T. Balstad, G. Stene, V. Baracos, A. Bye, F. Strasser, M. Fallon, K. Fearon
Journal: Annals of Oncology (2017)